Equillium, Inc. (NASDAQ:EQ – Get Free Report) fell 2% on Wednesday . The company traded as low as $0.67 and last traded at $0.67. 91,030 shares traded hands during trading, a decline of 74% from the average session volume of 355,583 shares. The stock had previously closed at $0.68.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Equillium in a research note on Wednesday, June 5th.
Check Out Our Latest Stock Report on EQ
Equillium Stock Performance
Equillium (NASDAQ:EQ – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $10.69 million during the quarter, compared to analyst estimates of $9.15 million. Equillium had a negative return on equity of 51.20% and a negative net margin of 32.01%. As a group, equities research analysts expect that Equillium, Inc. will post -0.12 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Equillium
An institutional investor recently bought a new position in Equillium stock. Decheng Capital LLC purchased a new stake in Equillium, Inc. (NASDAQ:EQ – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,447,308 shares of the company’s stock, valued at approximately $3,215,000. Equillium makes up 0.9% of Decheng Capital LLC’s investment portfolio, making the stock its 18th largest holding. Decheng Capital LLC owned about 12.66% of Equillium as of its most recent filing with the SEC. Institutional investors own 27.05% of the company’s stock.
Equillium Company Profile
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
Featured Stories
- Five stocks we like better than Equillium
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.